Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

被引：21

作者：

Harshman, Lauren C. ^{[1
]}

Kuo, Calvin J. ^{[2
]}

Wong, Bryan Y. ^{[3
]}

Vogelzang, Nicholas J.

Srinivas, Sandy

机构：

[1] Stanford Univ, Div Oncol, Sch Med, CCSR, Stanford, CA 94305 USA

[2] Stanford Univ, Div Hematol, Sch Med, Stanford, CA 94305 USA

[3] Nevada Canc Inst, Div Hematol & Oncol, Las Vegas, NV USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 08期

关键词：

Bevacizumab; Erythropoiesis; Increased hemoglobin; Renal cell carcinoma; VEGF inhibition; GROWTH-FACTOR RECEPTOR; DOUBLE-BLIND; SUNITINIB; BEVACIZUMAB; SU11248; ALPHA; TRIAL; KIT;

D O I：

10.1080/07357900902744528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively analyzed whether increased hemoglobin is a surrogate biomarker of efficacy for vascular endothelial growth factor (VEGF) inhibitors in advanced renal cell carcinoma (RCC) patients. Twelve patients were identified who had received bevacizumab alone or as combination therapy. Eleven patients experienced a rise in hemoglobin. Median change was 1.6 g/dL (0-4.0). Degree of peak increase correlated with longer progression-free survival (PFS) in metastatic patients: increase of 15% yielded a 3.1-month median PFS compared to 8.2 months with rises 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy.

引用

页码：851 / 856

页数：6

共 34 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib [J].

Alexandrescu, Doru T. ;

McClure, Rebecca ;

Farzanmehr, Haleh ;

Dasanu, Constantin A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4047-4048

[3] Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma REPLY [J].

Alexandrescu, Doru T. ;

Dasanu, Constantin A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :473-474

[4]

[Anonymous], J CLIN ONCOL

[5]

[Anonymous], J CLIN ONCOL

[6]

BIBB JL, 2007, GASTR CANC S

[7]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[8] Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia [J].

Canon, JL ;

Vansteenkiste, J ;

Bodoky, G ;

Mateos, MV ;

Bastit, L ;

Ferreira, J ;

Rossi, G ;

Amado, RG .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (04) :273-284

[9] The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from rive randomized clinical trials [J].

Cella, D ;

Kallich, J ;

McDermott, A ;

Xu, X .

ANNALS OF ONCOLOGY, 2004, 15 (06) :979-986

[10]

Choi YM, 2007, J CLIN ONCOL, V25

← 1 2 3 4 →